FDA advisory panels: technical input needs rank above COI (conflict of interest) issues
This article was originally published in Clinica
The US FDA must give prior public notice before letting experts with a potential conflict of interest (COI) participate on advisory panels, according to a bill enacted by the US Congress last week.
You may also be interested in...
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.